Compounders urge FDA to reject Wyeth petition

The International Academy of Compounding Pharmacy (IACP) has urged the FDA to reject Wyeth's citizen's petition to place restrictions on compounded bioequivalent hormone replacement therapy (BHRT). The petition "does not aim to protect women's health, just Wyeth's wealth," by trying to impose far-ranging restrictions on physicians' ability to prescribe and pharmacists' ability to compound BHRT, contended IACP executive director L. D. King.